Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women.
Seven women suffering from hypogonadism due to previous hypophysectomy, isolated gonadotrophin deficiency, or Kallman's syndrome [median age 39 years (range 24-45)] volunteered to participate in a study to assess ovarian response following multiple-dose administration of recombinant human follicle-stimulating hormone (rhFSH; Org 32489). Baseline serum FSH and luteinizing hormone (LH) concentrations were 0.25 (< 0.05-1.15) IU/l and 0.06 (< 0.05-0.37) IU/l, respectively. Subjects received daily i.m. injections of rhFSH for 3 weeks (week 1: 75 IU/day, week 2: 150 IU/day, week 3: 225 IU/day). Blood sampling and sonographic investigations were performed on alternate days. Steady-state FSH concentrations were reached approximately 3-5 days after alterations of the doses administered. Maximum FSH concentrations were between 7.1 and 11.8 IU/l, whereas serum LH concentrations remained unchanged. Due to absent follicle development and lack of a rise in immunoreactive inhibin (INH) (response failure possibly due to early ovarian failure or resistant ovary syndrome) in two subjects, analysis of ovarian response was restricted to five volunteers. Serum androstenedione levels showed no significant changes during rhFSH administration. Although serum immunoreactive INH concentrations reached normal late follicular values [659 (388-993) IU/l], serum oestradiol revealed only a minor increase [77 (18-210) pmol/l]. Moreover, growth of (multiple) ovarian follicles was observed up to pre-ovulatory sizes (> 15 mm) in these patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Schoot
D C
DC
Department of Obstetrics and Gynaecology, Dijkzigt University Hospital, Rotterdam, The Netherlands.
Harlin
J
J
Shoham
Z
Z
Mannaerts
B M
BM
Lahlou
N
N
Bouchard
P
P
Bennink
H J
HJ
Fauser
B C
BC
D000328:Adult; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006065:Gonadotropins, Pituitary / Q000172:deficiency*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D007016:Hypophysectomy / Q000009:adverse effects; D007018:Hypopituitarism / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D007265:Inhibins / Q000097:blood; D017436:Kallmann Syndrome / Q000188:drug therapy / Q000503:physiopathology; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D006080:Ovarian Follicle / Q000187:drug effects / Q000502:physiology; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D006065:Gonadotropins, Pituitary; D011994:Recombinant Proteins; D007265:Inhibins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone